StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

NovoCure r&d expenses

Research and development expenses are spending on new products and technology.

NovoCure's R&D Expenses for the twelve months ending Sep 30, 2026 was $228.79M, up 6.5% year over year. For fiscal 2025 it was $224.54M, up 7.1% from the year before. Over ten years it grew 17.8% a year on average. The highest annual figure on record is $224.54M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$224.54M+7.1%
FY2024Dec 31, 2024$209.65M-6.0%
FY2023Dec 31, 2023$223.06M+8.2%
FY2022Dec 31, 2022$206.09M+2.4%
FY2021Dec 31, 2021$201.30M+52.5%
FY2020Dec 31, 2020$132.01M+67.1%
FY2019Dec 31, 2019$79.00M+56.2%
FY2018Dec 31, 2018$50.57M+32.7%
FY2017Dec 31, 2017$38.10M-8.1%
FY2016Dec 31, 2016$41.47M-5.2%
FY2015Dec 31, 2015$43.75M+8.3%
FY2014Dec 31, 2014$40.38M+16.0%
FY2013Dec 31, 2013$34.80M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$58.10M+7.5%
Q2 FY2026Jun 30, 2026$51.45M-7.9%
Q1 FY2026Mar 31, 2026$58.34M+8.5%
Q4 FY2025Dec 31, 2025$60.91M+18.9%
Q3 FY2025Sep 30, 2025$54.03M+4.1%
Q2 FY2025Jun 30, 2025$55.83M+1.6%
Q1 FY2025Mar 31, 2025$53.78M+4.2%
Q4 FY2024Dec 31, 2024$51.21M-5.7%
Q3 FY2024Sep 30, 2024$51.88M-3.2%
Q2 FY2024Jun 30, 2024$54.96M-0.9%
Q1 FY2024Mar 31, 2024$51.60M-13.6%
Q4 FY2023Dec 31, 2023$54.31M-0.9%
Q3 FY2023Sep 30, 2023$53.62M+3.2%
Q2 FY2023Jun 30, 2023$55.43M-2.9%
Q1 FY2023Mar 31, 2023$59.70M+41.4%
Q4 FY2022Dec 31, 2022$54.82M-3.7%
Q3 FY2022Sep 30, 2022$51.96M+7.9%
Q2 FY2022Jun 30, 2022$57.08M+13.4%
Q1 FY2022Mar 31, 2022$42.23M-8.0%
Q4 FY2021Dec 31, 2021$56.93M+29.4%
Q3 FY2021Sep 30, 2021$48.14M+46.7%
Q2 FY2021Jun 30, 2021$50.32M+68.2%
Q1 FY2021Mar 31, 2021$45.92M+81.7%
Q4 FY2020Dec 31, 2020$44.00M+85.3%
Q3 FY2020Sep 30, 2020$32.82M+74.9%
Q2 FY2020Jun 30, 2020$29.92M+53.8%
Q1 FY2020Mar 31, 2020$25.27M+48.3%
Q4 FY2019Dec 31, 2019$23.74M+57.9%
Q3 FY2019Sep 30, 2019$18.77M+43.5%
Q2 FY2019Jun 30, 2019$19.45M+71.2%
Q1 FY2019Mar 31, 2019$17.04M+53.5%
Q4 FY2018Dec 31, 2018$15.03M+49.6%
Q3 FY2018Sep 30, 2018$13.07M+41.0%
Q2 FY2018Jun 30, 2018$11.36M+21.2%
Q1 FY2018Mar 31, 2018$11.10M+18.0%
Q4 FY2017Dec 31, 2017$10.05M+18.6%
Q3 FY2017Sep 30, 2017$9.27M–
Q2 FY2017Jun 30, 2017$9.37M–
Q1 FY2017Mar 31, 2017$9.41M–
Q4 FY2016Dec 31, 2016$8.47M–

More NovoCure figures

See a number that looks wrong?